Literature DB >> 1430082

Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia.

N Hattori1, T Ishihara, K Ikekubo, K Moridera, M Hino, H Kurahachi.   

Abstract

We have demonstrated the presence of anti-PRL autoantibody in 5 patients with idiopathic hyperprolactinemia. The clinical features were suggestive of a weak biological activity of PRL, such as regular menses and no galactorrhea. Total PRL levels were markedly elevated (685 +/- 386 micrograms/L) (mean +/- SD) and the proportion of the bound form was 90.7 +/- 7.1%. Scatchard analysis revealed a low-affinity, high-capacity antibody: the association constant was 0.73 +/- 0.56 x 10(7) mol-1 and the maximal binding capacity was 2139 +/- 1792 micrograms/L. Gel filtration study showed that a substantial amount of PRL (64.6 +/- 19.5%) was eluted at the position of 150,000-170,000 mol wt PRL (big-big PRL). Immunoprecipitation study using the chain-specific antibodies showed that the anti-PRL autoantibody belonged to kappa-type immunoglobulin G. These results may indicate that there exists autoantibody-related hyperprolactinemia, especially in those with particularly high serum PRL levels, who had previously been diagnosed as "idiopathic" hyperprolactinemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430082     DOI: 10.1210/jcem.75.5.1430082

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Prevalence and reproductive manifestations of macroprolactinemia.

Authors:  Amanpreet Kaur Kalsi; Ashutosh Halder; Manish Jain; P K Chaturvedi; J B Sharma
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

Review 2.  Neuroendocrine causes of amenorrhea--an update.

Authors:  Lindsay T Fourman; Pouneh K Fazeli
Journal:  J Clin Endocrinol Metab       Date:  2015-01-12       Impact factor: 5.958

3.  Macroprolactinemia in hyperprolactinemic infertile women.

Authors:  Krithika Thirunavakkarasu; Pinaki Dutta; Subbiah Sridhar; Lakhbir Dhaliwal; G R V Prashad; Shalini Gainder; Naresh Sachdeva; Anil Bhansali
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

4.  Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions.

Authors:  G M Gambino; P Beck-Peccoz; S Borgato; G Faglia; A Spada; L Persani
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

5.  Recombinant human prolactin for the treatment of lactation insufficiency.

Authors:  Camille E Powe; Maureen Allen; Karen M Puopolo; Anne Merewood; Susan Worden; Lise C Johnson; Amy Fleischman; Corrine K Welt
Journal:  Clin Endocrinol (Oxf)       Date:  2010-11       Impact factor: 3.478

6.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

7.  Antiprolactin autoantibodies are associated with hyperprolactinemic status in men infected with human immunodeficiency virus.

Authors:  Alfredo Leaños-Miranda; Iris Contreras-Hernández
Journal:  Endocrine       Date:  2002-11       Impact factor: 3.925

Review 8.  Macroprolactinemia: diagnostic, clinical, and pathogenic significance.

Authors:  Akira Shimatsu; Naoki Hattori
Journal:  Clin Dev Immunol       Date:  2012-12-04

9.  Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice.

Authors:  Vaishya Richa; Gupta Rahul; Arora Sarika
Journal:  J Reprod Infertil       Date:  2010-10

10.  Frequency of Macroprolactinemia in Hyperprolactinemic Women Presenting with Menstrual Irregularities, Galactorrhea, and/or Infertility: Etiology and Clinical Manifestations.

Authors:  Alfredo Leaños-Miranda; Karla Leticia Ramírez-Valenzuela; Inova Campos-Galicia; Rosario Chang-Verdugo; Lizbeth Zarela Chinolla-Arellano
Journal:  Int J Endocrinol       Date:  2013-09-30       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.